The pharmacologic basis for therapeutic interest in bupropion.
Bupropion, a compound chemically dissimilar to tricyclic antidepressants and monoamine oxidase inhibitors, was found to be active in animal models that are predictive of antidepressant activity in man. Bupropion was also found to be pharmacologically and biochemically distinct from tricyclics and monoamine oxidase inhibitors. Furthermore, it lacked anticholinergic activity, was not sympathomimetic, and was at least 10-fold weaker as a cardiac depressant than the tricyclic antidepressants. It was concluded that bupropion would be better tolerated and safer in man than standard therapies and that its pharmacologic and biochemical profile held out the possibility of novel antidepressant actions.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D016642:Bupropion; D003216:Conditioning, Operant / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D051379:Mice; D008954:Models, Biological; D009043:Motor Activity / Q000187:drug effects; D011427:Propiophenones / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013747:Tetrabenazine / Q000037:antagonists & inhibitors
D000928:Antidepressive Agents; D011427:Propiophenones; D016642:Bupropion; D013747:Tetrabenazine